A number of other research analysts have also issued reports on VEC. Shore Capital reiterated a “hold” rating on shares of Vectura Group in a research report on Tuesday, September 10th. Peel Hunt reiterated a “hold” rating on shares of Vectura Group in a research report on Monday, November 4th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Vectura Group currently has an average rating of “Buy” and an average target price of GBX 133.50 ($1.74).
Shares of LON:VEC traded down GBX 3.20 ($0.04) during midday trading on Thursday, reaching GBX 84.50 ($1.10). 736,225 shares of the company’s stock traded hands, compared to its average volume of 4,610,000. Vectura Group has a 1 year low of GBX 0.91 ($0.01) and a 1 year high of GBX 97.66 ($1.28). The company has a market cap of $529.16 million and a P/E ratio of -6.60. The company has a debt-to-equity ratio of 1.73, a quick ratio of 2.41 and a current ratio of 2.84. The company has a fifty day simple moving average of GBX 85.54 and a two-hundred day simple moving average of GBX 81.13.
About Vectura Group
Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta and Anoro Ellipta for the treatment of COPD.
Further Reading: Market Indexes
Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.